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Abstract 
The drug discovery process can be accelerated by chromatographic profiling of the analogs to model in vivo 
distribution and the major non-specific binding. A balanced potency and chromatographically determined 
membrane and protein binding (IAM MB/PB) data enable selecting drug discovery compounds for further 
analysis that have the highest probability to show the desired in vivo distribution behavior for efficacy and 
reduced chance for toxicity. Although the basic principles of the technology have already appeared in 
numerous publications, the lack of standardized procedures limited its widespread applications especially in 
academia and small drug discovery biotech companies. In this paper, the standardized procedures are 
described that has been trademarked as Regis IAM MB/PB Technology®. Comparison between the Drug 
Efficiency Index (DEI=pIC50-logVdu+2) and generally used Ligand Lipophilicity Efficiency (LLE) has been 
made, demonstrating the advantage of measured IAM and HSA binding over calculated log P. The power of 
the proposed chromatographic technology is demonstrated using the data of marketed drugs.  
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Introduction 
Medicinal chemists face multi-factorial challenge problems when designing drug molecules that can 
reduce the impact or cure a pathological condition; drug discovery scientists seek the smallest possible 
dose with minimal side effects [1-4]. Screening cascades often generate vast quantities of primarily in-vitro 
data, and in some cases, in vivo data on compounds that form a decision on which compounds are selected 
for further progression. This paper documents an alternative screening triage which can help to avoid the 
problem of analysing too much discovery data when choosing lead compounds to pursue. 
Chemical structure design of discovery molecules usually focuses on elucidating the structure – activity 
relationships after identifying the target enzyme/receptor followed by the development of a potency 
screening method. The active molecules are then tested for a variety of assays for affinity and 
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developability, such as enzyme assays, selectivity assays, cellular assays, CaCo2 or MDCK cell permeability, 
solubility [5], lipophilicity, microsomal stability, Hep G cell hepatotoxicity, cellular toxicity, [6] etc. All future 
reference to receptors will have dual meaning referring to either receptor or enzyme targets, for simplicity. 
Project teams usually design screening cascades to guide the filtering process of compounds after each 
measurement, to ensure those compounds that do not meet pre-defined criteria in a particular assay are 
eliminated from further screening. This sequential screening process frequently excludes compounds with 
good in vivo drug properties; marketed drugs have appropriate in vivo properties for the disease they are 
being developed to treat, along with sufficient potency to engage the target and produce the desired 
effect. The discovery challenge is to recognise that discovery compounds may exhibit high potency, but 
they may lack acceptable in vivo distribution enabling the compound to achieve a therapeutic free drug 
concentration at the target receptor in the target tissue(s) in vivo. In vivo properties, particularly 
distribution, are as important as high potency or receptor occupancy. Regardless of this fact, none of the 
properties which are typically measured during compound screening is on their own sufficient to predict 
the compound’s fate in vivo or in human clinical trials. This must ultimately be measured. Several other 
properties should also be measured, which include target binding, selectivity, absorption, distribution, 
metabolism and elimination (ADME), pharmacokinetics and pharmacodynamics (PK/PD) profile, and of 
course the safety profile. 
In order to find good absorption and bioavailability, chemists have to design molecules which will have 
good solubility and permeability, and in general lipophilicity. Designing a drug candidate which has good 
clinical ADME properties, is often much different than designing discovery compounds with simply high 
receptor binding or potency. Various ligand efficiency parameters have been introduced and frequently 
used by medicinal chemists that relate the measured potency to some calculated properties of the 
compounds such as, size and lipophilicity as it has been recently reviewed [7-8]. This manuscript describes 
how chromatographic analysis can efficiently predict or help select which compounds have the greater 
probability of becoming lead molecules by balancing the receptor binding or potency with optimum 
compound distribution in vivo. 
Obviously, achieving good oral absorption alone is not sufficient when choosing a drug candidate. 
Overcoming the body’s natural defense mechanisms is also necessary to achieve relevant oral 
bioavailability as nature has evolved animal and human protection against potentially harmful xenobiotics. 
Some of these defense mechanisms we need to consider when developing NCE’s are: (i) gut metabolism, (ii) 
efflux processes and (iii) first pass metabolism. Thus, ensuring that discovery molecules are not subject to 
active efflux and quick elimination or metabolism is current mainstream thinking in most drug discovery 
processes. 
The latest studies show that the most significant problem with the late-stage attrition of discovery 
molecules is related to safety and efficacy. Many safety-related issues have been directly attributed to the 
lipophilicity of compounds [9-12] especially when it is measured using Immobilized Artificial Membranes 
(IAMs).  High IAM binding is indicative of the compound’s binding to multiple targets or receptors, this is 
often referred to as compound promiscuity. This may cause unwanted pharmacology or toxicity. It has 
previously been shown that compounds that require lower clinical dose (ranging between 1-100 mg) and 
therefore lower efficacious plasma concentrations are less likely to cause toxicity [9,13].  
The root cause of these problems is partially dominated by the compounds binding or partitioning into 
tissue which is predominantly comprised of membrane phospholipids; when this happens, the drug is 
sequestered into non-specific phospholipid binding sites and is then less available as a free drug near the 
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target of interest. Plasma proteins can also reduce the amount of free drug available to interact with 
enzymes/receptors (and when this happens an increased dose is essential). Thus, the non-specific 
binding/partitioning of compounds to phospholipids and proteins reduce the available free concentration 
at the site of action. Thus, increased doses are needed for activity, but, this increases the possibility of 
undesired pharmacology or toxicity.  
This paper focuses on the role of distribution in the Absorption, Distribution, Metabolism and 
Elimination (ADME) process, without neglecting the absorption and clearance that regulate the magnitude 
and the frequency of dosing. We propose to design and triage NCEs based on their in vitro distribution 
behavior that determines the amount/concentration of compounds in various tissue compartments, and 
the free unbound compartments that are responsible for safety issues and efficacy, respectively. This can 
be achieved by using some of the major protein components which make up tissues in the body as 
chromatographic stationary phases, this is called biomimetic chromatography and has been recently 
reviewed [14].  
We also propose that the unbound volume of distribution of compounds is an important parameter to 
consider, as this in vivo parameter describes the proportion of the dose relative to the free plasma 
concentration of compounds in steady state [15]. Based on the free drug hypothesis, [16] the free plasma 
concentration is the same as the free tissue concentration, when no permeability barrier or active transport 
distorts the thermodynamic equilibrium, between plasma and tissues which contain the therapeutic 
targets. Though active transporters may have a significant effect on the free concentration of a drug on the 
two sides of the membrane [17], the concentration difference can be explained by strong binding of the 
drug to intracellular components. The free concentration difference is usually not more than an order of 
magnitude on the two sides of the membrane due to active transporters that require constant energy 
supply to keep the concentration difference. Distorting the thermodynamic equilibrium by two to three 
orders of magnitude would require constant energy supply (ATP), and the active transporters may become 
easily saturated.  
The unbound volume of distribution can be considered as a proportional parameter to the drug partition 
coefficient between the free and bound compartments. In this respect, it is very similar to the recently 
introduced drug efficiency parameter that relates the free bio-phase concentration to the dose. The drug 
efficiency concept that was introduced by Braggio [18] highlights the importance of the free concentration 
of the drug in the biophase near the target relative to the dose to achieve efficient PK/PD of a drug 
molecule. The drug efficiency index, DEI highlights the importance of balancing the potency and drug 
efficiency of the molecules and is proposed as an alternative parameter to simply focusing on potency, as 
other ligand efficiency parameters tend to be biased towards [19]. The DEI concept also helps designing 
drug molecules with a low therapeutic dose that in turn reduce general toxicity. 
Table 1 shows the abbreviations and their meaning of the properties that are investigated in this paper, 
while Table 2 shows the equations how they are calculated and how they are related to each other. 
The drug distribution properties are most often characterised by lipophilicity. Lipophilicity has been 
recognised for a long time as the principal parameter that influences solubility [20,21], permeability [22], 
tissue binding, protein binding [23,24], toxicity [10], promiscuity [1], clearance [25] etc. Several ligand 
efficiency parameters contain the lipophilicity and propose to consider the potency relative to the 
lipophilicity of the compounds, such as Ligand Lipophilicity Efficiency, LLE [7,26]. Recently, the 
chromatographic lipophilicity has been combined with the number of aromatic rings in the molecules to 
derive the Property Forecast Index (PFI) [27]. It has been suggested that having a PFI value less than 6 for 
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drug discovery compounds increases the probability of improving drug attrition rates. 
Table 1. Variables, abbreviations used throughout the text 
IAM Immobilized Artificial Membrane (HPLC stationary phase_ 
HSA Human Serum Albumin 
AGP Alpha-1-acid-glycoprotein 
PPB Total plasma protein binding 
MB Membrane Binding (measured by IAM) 
MB/PB Membrane binding and protein binding 
Vdss Steady state volume of distribution (dose/plasma concentration) 
Vdu Steady state unbound volume of distribution (dose/free plasma concentration= Vd/fu) 
fu Unbound fraction in plasma 
DE Drug efficiency (100* free biophase conc/dose) 
DEmax Drug efficiency measured by MB/PB by HPLC (100*free plasma conc/dose) 
DEI Drug efficiency index, potency plus log DEmax (pIc50 +log DE) 
IAM MB Membrane binding index, previously known as CHI(IAM) 
clogP Calculated logarithm of octanol/water partition coefficient 
Log D/P Logarithm of distribution/partition coefficient 
 
Table 2. Equations used to predict distribution properties 
log K(IAM); Eq. (1) = 0.29*e
(0.026MB+0.42) 
+0.7 
log K(HSA); Eq. (2) = e
log k(HSA) 
log k(HSA)  = log(%HSAbound/(101- %HSA bound)) 
Estimated log Vdss; Eq. (3) = 0.44*log K(IAM) -0.22*log K(HSA) – 0.62 
Estimated log Vdu; Eq. (4) = 0.23*log K(HSA) +0.43*log K(IAM) -0.72 
DEmax; Eq. (7) = 100/Vdu 
LLE Ligand lipophilicity efficiency (pIC50 -clogP) 
log k (PPB) (8) 0.87 ∗ log 𝑘(𝐻𝑆𝐴) + 0.17 ∗ log 𝑘(𝐴𝐺𝑃) + 0.06 ∗ 𝑐𝑀𝑅 − 0.27 
 
Lipophilicity has been historically characterised by the octanol/water partition coefficient, log P, for the 
neutral form of the molecules and by the distribution coefficient, log D, measured at different pHs, mainly 
at pH 7.4. Log P is widely used since the work of Hansch [28] who suggested log P to describe the so-called 
“random” walk of the drug molecule that reduces its free concentration near the receptor. Lipophilic 
compounds energetically do not favour residing in the aqueous environment and have a preference to 
“stick” to any hydrophobic surface in the body. The octanol/water system is able to partially mimic the 
polar groups with hydrogen bond donor and acceptor properties that may be present in the lipophilic 
environment in the body and therefore serve as a good model to describe biological distribution. However, 
the octanol/water lipophilicity and any other lipophilicity measure that does not include cellular 
membranes and proteins, fails to explain the biological distribution of molecules when they have charge or 
special shape. An example is the comparison of nifedipine and amlodipine (see Figure 1). Nifedipine is more 
lipophilic at physiological pH but still, the volume of distribution of amlodipine is 30 times higher, indicating 
30 times higher partitioning to tissues then nifedipine. The clearance of nifedipine is 9.8 mL/min/kg [29], 
and clearance of amlodipine is in a similar range, 7 mL/min/kg [30]. The major difference between the two 
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molecules is a basic amine group on amlodipine. The basic group results in amlodipine having a stronger 
binding to phospholipids than albumin, and this results in a large difference in their volumes of distribution. 
 
Figure 1. Physico-chemical and biomimetic properties of nifedipine and amlodipine 
 
Besides measuring the octanol/water partition coefficients we propose a method of measuring the 
protein and phospholipid binding of the compounds using reverse phase high-performance liquid 
chromatography in conjunction with the Membrane Binding/Protein Binding Technology (MB/PB 
Technology®) registered to Regis Technologies inc. Using this approach, we can measure compounds 
interaction with phosphatidylcholine membrane (IAM), human serum albumin (HSA) and alpha-1-acid 
glycoprotein (AGP). These are commercially available HPLC stationary phases that contain or mimic these 
constituents of the body. These include (i) IAMs, (ii) chiral HSA and (iii) chrial AGP. 
The IAM concept was introduced by Pidgeon et al. [31-33] and it was the first attempt to emulate the 
biological membrane on a solid surface. HPLC columns with IAM stationary phase where the 
phosphatidylcholine moiety is chemically bonded to a solid surface mimic the density of 
phosphatidylcholine in the biological membrane bi-layer. Other approaches do exist for measuring 
membrane binding such as using liposome partition measurements or micellar electrophoresis [35-36]. 
However, they have their limitations and are also very time-consuming. Biomimetic stationary phases have 
been validated by comparing the retention times obtained on the commercially available ChiralPak-HSA  
[37-39] and ChiralPak-AGP [40-41] stationary phases result in binding values that are proportional to the 
albumin and AGP binding of compounds obtained by equilibrium dialysis. When using biomimetic 
stationary phases the retention time of the compounds is directly proportional to the dynamic equilibrium 
constant between the mobile phase (buffer at physiological pH) and the actual body component 
(membrane and proteins) in the stationary phase. The process is very similar to the biological distribution 
processes that are also dynamic (never in real equilibrium unless at steady state) and occurs on the surfaces 
of the biomimetic stationary phases. The measured membrane binding parameters reflect the three-
dimensional nature of the molecule’s interaction within an in vivo system (the drug, membrane and protein 
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stationary phase) that has been demonstrated in the literature [14]. The chromatographic technique to 
measure these biomimetic properties has several other technical advantages. It can be easily automated; 
there is no need for concentration determination and measurements. The important thing is, however, to 
standardise the retention times and binding data by measuring a calibration set of compounds with each 
compound set to be able to get normalised retention times for each of the stationary phases being used to 
generate binding data (IAM, HSA and AGP). A detailed description of the standardised methodology for 
each of the IAM MB/PB stationary phases has recently been published  [14].  
There are several publications establishing the usefulness of the IAM MB/PB technology to model in vivo 
drug distribution, such as the volume of distribution model [42], unbound volume of distribution model 
[43-44] and how they can be used to screen compounds in early drug discovery [45].  It was found that 
strong IAM MB (CHI IAM > 50) can be related to phospholipidosis [46-47], as well as high volume of 
distribution and tissue partitioning [43]. Recently, it was found that promiscuity (i.e., a discovery compound 
binding to multiple receptors) showed good correlation to the IAM MB of drug discovery compounds. The 
IAM MB data showed a good correlation with the intracellular concentration of compounds, indicating that 
membrane binding is important to get compounds into the cell [48]. Estimating the potential clinical dose 
as early as possible is an important aspect of the drug discovery process to help select the optimal 
compound profile and highest probability of successful progression to the clinic [49-50]. Valko et al. [51] 
highlighted that the maximum achievable drug efficiency (DEmax) that can be obtained assuming (i) 100 % 
bioavailability, (ii) no permeability barrier and (iii) no active transport could be calculated using in vitro 
biomimetic measurements, essentially the Regis IAM MB/PB Technology® that we are proposing in this 
paper as a useful tool in early drug discovery [51]. The drug efficiency concept as a design parameter has 
the advantage that it can be estimated from in vitro measurements, and can be monitored during the drug 
development process to see how the early estimation performs when in vivo measurements become 
available pre-clinically, or from human clinical trials. In this paper, the intention is to show the models and 
the applicability of the Regis IAM MB/PB Technology® in early drug discovery. It is also important to have 
the ability to estimate these in vitro properties from the chemical structure thus helping the design stage of 
the molecules too. It has been shown that the retention of compounds obtained on the proposed 
biomimetic stationary phases can be estimated in silico [52-55], however it is worth noting that the in silico 
models use 2D molecular descriptors that are not sufficient to estimate the 3D contribution of the 
molecules binding to proteins, therefore they can be used only as a rough estimations. 
Phospholipids constitute approximately 40 % of the human body, therefore, the phospholipid binding of 
compounds are a very important parameter that should not be ignored in the drug design process. It was 
found that MB IAM values above 50 indicate promiscuous binding [57], and higher phospholipidotic 
potential [56-59] for discovery compound.  It was also found that MB IAM showed a good correlation with 
the total cellular concentration of discovery compounds [60].  
In this paper, we present the models for human clinical unbound volume of distribution and drug 
efficiency using measured biomimetic properties, and we describe a protocol how to use these data in early 
lead optimisation.  
Experimental  
The values for dose, potency (pIC50), the volume of distribution, clearance, the half-life of the known 
drugs were obtained from various databases (www.drugbank.ca/drugs and www.drugs.com) and listed in 
Table A1. The measured IAM MB/PB data are published in the book by Valko [45] and listed in Table A2. 
Table A2 contains the estimated volume of distribution (IAM MB/PB log Vdss) and the estimated unbound 
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volume of distribution (IAM MB/PB log Vdu) using the published models [42-43], and the  Regis IAM MB/PB 
Technology®. The same technology has been applied to estimate the Maximum Drug Efficiency (HPLC 
DEmax) value, that represents the maximum drug efficiency that can be achieved when the bioavailability is 
100 %, and there is no permeability barrier or active transport to disturb the steady state equilibrium. This 
can be expressed as the reciprocal value of the steady-state unbound volume of distribution [51]. 
The IAM MB data were obtained using IAM PC.DD2 HPLC column (Regis Technologies, Inc., Il, USA) with 
the dimensions of 100 x 3 mm. Mobile phase A was 50 mM ammonium acetate adjusted to pH 7.4, while 
mobile phase B was 100 % acetonitrile. The flow rate was 1.5 mL/ min, the linear gradient was 0 to 80 % 
acetonitrile in 0 to 5 min, 5 to 5.25 min 80 % acetonitrile then back to 0 % acetonitrile by 5.5 min. The total 
run time is 7 min. The calibration set of compounds are listed in Table 3 and the calibration test solution is 
available from Bio-Mimetic Chromatography, UK (www.bio-mimetic-chromatography.com). A typical 
chromatogram is shown in Figure 2. 
It is essential to obtain a straight line between the retention times and the IAM MB index of the 
calibration set of compounds. Moreover, it is essential to run a system suitability test of compounds (2 
neutral, 2 basic and 2 acidic compounds) listed in Table 4, and check that the measured IAM MB data are 
the same +/- 5 units listed in the table. This ensures that the IAM phospholipid immobilised phase is 
maintained, preserving the natural phospholipid density on the column. 
 
Figure 2. A typical chromatogram obtained on IAM PC.DD2 100 x 3 mm HPLC column. Flow rate: 1.5 mL/min, 
mobile phase A; 50 mM ammonium acetate adjusted to pH 7.4, B: acetonitrile. Run time 7 min; Gradient: 0 to 
5 min 0 to 80 % B, 5 to 5.25 min 80 % B, 5.25 to 5.5 min 0 % B 
It was found that the log k(IAM) shows a non-linear relationship with log P octanol/water values [42]. To 
convert the log k(IAM) scale to the log P scale we need the transformation as shown by equation (1). The 
converted log K(IAM) data is equivalent to the partition coefficient of the compound between the pH 7.4 
buffer and the phospholipid phase. 
log K(IAM)= 0.29* e(0.046*MB IAM+0.42)  + 0.70  (1) 
This data are then be used in the models for the volume of distribution, unbound volume of distribution 
and the in vitro maximum drug efficiency (HPLC DEmax). 
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Table 3. The calibration set of compounds and their standard IAM MB score on IAM.PC.DD2 
column. The IAM MB data approximate to the acetonitrile concentration in the mobile phase 
when the compound elutes using the gradient conditions. The log k(IAM) values obtained as 
0.046IAM MB+0.42 where the constants have been derived by plotting isocratic log k(IAM) 
data extrapolated to 0 % acetonitrile mobile phase using isocratic measurements [52]. 
Compound Typical tR (min) IAM MB  log k(IAM) 
Octanophenone 3.18 49.4 2.69 
Heptanophenone 3.07 45.7 2.52 
Hexanophenone 2.94 41.8 2.34 
Valerophenone 2.79 37.3 2.14 
Butyrophenone 2.58 32 1.89 
Propiophenone 2.35 25.9 1.61 
Acetophenone 2.04 17.2 1.21 
Acetanilide 1.85 11.5 0.95 
Paracetamol 1.62 2.9 0.55 
 
Table 4. System suitability test compounds and their expected IAM MB 
data. The measured values should be within 5 IAM MB value agreements 
with the values in the table. Further drug molecules data can be found in 
reference [45]. 
Compound Acid/base IAM MB  
Carbamazepine Neutral 26.5 
Colchicine neutral 18.0 
Warfarin Acidic 16.0 
Indomethacin Acidic 24.5 
Nicardipine Basic 45.1 
Propranolol Basic 46.8 
 
The PB data are obtained on Chiralpack-HSA and ChiralPack AGP columns with the dimensions of 50 x 3 
mm. The flow rate was 1.5 mL/min and 2-propanol was used as mobile phase B, while mobile phase A is 50 
mM ammonium acetate adjusted pH to 7.4. The calibration set of compounds and their log k(HSA) and log 
k(AGP) data are listed in Table 5a and 5b. These data are derived from literature %HSA and %AGP binding 
data obtained by other methodology (equilibrium dialysis and ultrafiltration). These data are used to 
calibrate the gradient retention times on the protein column so that the binding data obtained from the 
retention times are comparable with binding data obtained by other methodologies. The typical retention 
times were obtained using a 6 min gradient run: 0 to 3 min 0 to 35 % 2-propanol, 3 to 4 min 35 % 2-
propanol, 4 to 4.2 min back to 0 % 2-propanol. Typical calibration plots and chromatograms have been 
published previously [14]. It was found that the obtained log k(HSA) showed a non-linear relationship with 
the log P values of acetophenone homologues [42]. To convert the log k(HSA) data to the log P scale we 
need to transform them using Equation 2. The so obtained log K(HSA) data are used in the models. 
log K(HSA) = elog k(HSA)                       (2) 
The published in vivo models used the above-described MB/PB data using the following equations 
below: 
MB/PB log Vdss= 0.44*log K(IAM)-0.22*log K(HSA) - 0.66                               (3) 
n=179   r2=0.76    s=0.33   
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where MB/PB log Vdss is the estimated in vivo steady state volume of distribution based on 179 known 
drugs human clinical data [42]. 
The model for the unbound volume of distribution has also been published previously using the 
available data for 70 marketed drugs [43] and shown by Equation 4. 
MB/PB log Vdu = 0.23 log K(HSA) + 0.43 log K(IAM) - 0.72                (4) 
n=70  r2= 0.84   s=0.32 
The HPLC DEmax data were calculated using the reciprocal value of the MB/PB log Vdu data and validated 
against human clinical DEmax data [51]. 
Table 5. The literature % binding data and the log k(HSA) (a) and log k(AGP) (b) data for the 
calibration set of compounds. The logarithmic retention times measured under a given condition 
should result in a straight line when plotted against the log k data. The regression coefficient 
should be above 0.96 and the warfarin enantiomers should be baseline separated in order to pass 














Warfarin 3.267 0.51 97.90 1.50 
Paracetamol 0.285 -0.55 14.00 -0.79 
Nizatidine 0.293 -0.53 20.40 -0.60 
Trimethoprim 0.512 -0.29 37.60 -0.23 
Propranolol 0.895 -0.05 66.60 0.29 
Carbamazepine 1.216 0.08 75.00 0.46 
Nicardipine 2.374 0.38 95.00 1.20 
Indomethacin 4.117 0.61 99.50 1.82 




calibration set of compounds 
Typical 
tR min 





%AGP as log 
(%AGP/(101-%AGP)) 
Warfarin 3.72 0.57 83.2 0.67 
Acetaminophen 1.16 0.06 3.2 -1.49 
Nizatidine 2.19 0.34 37.1 -0.24 
Trimethoprim 2.50 0.40 46.2 -0.07 
Propranolol 3.86 0.59 86 0.76 
Carbamazepine 3.21 0.51 73.2 0.42 
Nicardipine 4.08 0.61 92 1.01 
Indomethacin 2.98 0.47 52.9 0.04 
Diclofenac 3.09 0.49 69.3 0.34 
 
For the calculation of the stepwise regression equations, the academic version of JMP (SAS Institute) 
software has been used. The calculation of the physicochemical parameters the Chemaxon and ACD 
software were used. For creating the plots the Sentira version 1.0.0.6 (Optibrium 2014) software has been 
used. 
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Results and discussion  
The importance of the unbound volume of distribution and the drug efficiency in the drug discovery 
process has been discussed in several recent papers focusing on the clearance and plasma protein binding 
[15-16]. There is a general consensus that the free concentration of the compound at the site of action 
drives clinical efficacy together with the high affinity for the target receptor. However, a significant debate 
remains regarding what determines the free concentration; the dose, dosing frequency, intrinsic clearance, 
plasma protein binding or volume of distribution, all are important factors that should be considered. We 
can depict a simplified model as it was described by Stepensky [15,61] and consider that the dosing amount 
and frequency required to balance the elimination rate of a compound determines the amount of drug in 
the body. While the volume of distribution describes how the total amount of drug distributes between the 
tissue and plasma compartment, unbound volume of distribution describes the drug distribution between 
the free and bound compartments regardless of the location where the drug binds (tissues or plasma 
proteins, see Figure 3). 
While investigating known drugs it was clear that the volume of distribution showed no correlation 
alone to clearance or half-life. However, it did show a good correlation with the product term (or the sum 
of their logarithmic values clearance and half-life) as is shown in Figure 4a, b and c. The data supports the 
statement that the distribution properties of compounds are an independent parameter from the 
clearance. 
 
Figure 3. The schematic absorption, distribution and elimination process 
 
The tissue/plasma partition coefficient of a compound can be defined as the tissue concentration 
divided by the plasma concentration of the compounds. The concentration can be expressed as the amount 





                                         (5) 
 
where the amount of drug in tissues equals the dose minus the amount in plasma (Ap), Vt is the tissue 
volume, Vp is the plasma volume. As the steady-state volume of distribution (Vdss) equals the dose over the 
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plasma concentration, introducing that into Equation 5 we can express the tissue plasma partition as a 





                                             (6) 
 
In turn, the volume of distribution of marketed drugs could be modeled by the difference in the 
membrane and the protein binding of compounds as described by Equation 3 and shown in Figure 5 for the 
investigated compounds. There are only 40 compounds that have been included in the training set, the 
majority of the compounds were not included in the original model. That explains that the statistics are 
slightly worse (r2 = 0.76; root mean square error = 0.33 in the original model, while here the r2 = 0.57 and 





Figure 4. The plot of log Vdss vs log in vivo CL (a), log Vdss vs log T½ (b) and log Vdss vs the sum of log CL and log 
T½. 
 
The unbound volume of distribution is in principle the reciprocal value of the maximum drug efficiency 
(DEmax) defined by Braggio et al. [18], that is defined by the proportion of the free bio-phase concentration 
and the dose. If the free drug hypothesis is true, which means the free plasma concentration if similar to 
(a) (b) 
(c) 
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the free tissue concentration of the compounds when no permeability barrier or active transport distorts 
the equilibrium, then the model for the unbound volume of distribution can be used to estimate the 
maximum drug efficiency (DEmax) of the compounds. Based on the definition of the Vdu and DEmax, their 





    (7) 
 
Figure 6 shows the unbound volume of distribution and the estimated DEmax of the marketed drugs 
listed in Table A1. In this case, only 10 compounds overlapped with the original training set.  Most of the 
compounds can be considered as a test set. The root-mean-square error increased from 0.32 to 0.45 while 
the r2 dropped from 0.84 to 0.66. The statistics for the training set is r2 = 0.76 and the standard error of the 
estimate is s = 0.33. The estimates can be considered as very predictive, as we have just used two major 
binding components in the body to describe the total non-specific binding of the compounds to the 
phospholipids and albumin type of proteins. 
 
 
Figure 5. The observed in vivo log Vdss vs the estimated Vdss by the IAM MB/PB Technology® using Equation 3. 
 
Figure 6. The plot of the human unbound volume of distribution and the estimated DEmax using the IAM 
MB/PB technology and Equation 4. 
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It is interesting to observe that the estimated DEmax of the marketed drugs is typically 1 % or just above. 
This also means that the unbound volume of distribution of marketed drugs is typically less than 100 L/kg. 
Thus, when we plot the potency (pIC50) values in the function of the Drug Efficiency Index (DEI), which is 
the sum of the pIC50 and the log DE, the marketed drugs are around the line of unity (see Figure 7). It has 
been observed [51] that discovery compounds usually have very narrow potency range (pIC50 between 7 to 
9), but a much broader range of drug efficiency index. Based on the retrospective analysis it turned out that 
compounds that are on the right side of the line of unity survived the strict candidate selection procedure 
and showed a good PK/PD profile [51]. 
 
Figure 7. The plot of potency in the function of DEI. The line of unity represents when the drug efficiency 
DE=1 %. The logarithm of 1 is zero, thus, DEI = pIC50. The yellow squares show project compounds [51], 
having the same good potency but a range of DEI. The candidate molecules (red stars) are on the right-hand 
side of the line where most of the marketed drugs are. 
It is interesting to note that we could not find any marketed drugs with drug efficiencies higher than 10-
15 %. This suggests that there should be an optimum proportion of the dose and free bio-phase 
concentration that is less than 10-15 % drug efficiency. It is very likely, that when the high proportion of the 
administered amount of compound is free then the elimination rate/clearance will be high and the various 
total tissue concentrations may be low. Therefore, we can optimise drug discovery compounds and triage 
them to have reasonably good potency if the drug efficiency is approximately 1 to 5 %. 
The Regis IAM MB/PB Technology® that use biomimetic HPLC stationary phases to measure the dynamic 
equilibrium constants of the compounds with the major binding components of the body enables the 
estimation of volume distribution and unbound volume of distribution without using in vivo 
experimentation for the fraction of the cost and time. 
It is also interesting to note that the DEmax values representing the sum of the albumin and 
phospholipid binding showed very good inverse correlation with clogP (much better than with clogD) [51]. 
This is because the log D drops whatever charge is present on the molecule at pH 7.4, however the sum of 
albumin and phospholipid binding change very little with the presence of charge. It is because positively 
charged compounds bind more strongly to IAM (phospholipids) while negatively charged compounds have 
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a stronger affinity to albumin type of proteins. That is why log P is a better model to use than log D [51]. 
Therefore, there is a connection between DEI and LLE. DEmax determined by the IAM MB/PB Technology is a 
better representation of the nonspecific binding of the compounds than log P as it is based on real albumin 
and IAM affinity of the compounds. In our earlier paper, we have shown that IAM MB/PB DEImax showed a 




Figure 8. Comparison of the relationship between in vivo log DEImax  vs LLE (a) and  IAM MB/PB log DEImax (b), 
respectively based on the analysis in reference [51]. 
 
The better fit is not surprising, as log P was intended to model the non-specific binding in the body 
caused by lipophilicity of the compounds. The IAM MB/PB technology provides the direct measurements of 
the major types of body components. Though AGP was not used in the models described above, it is mainly 
due to statistical reasons. The AGP binding and IAM MB binding showed a significant correlation, so it was 
not possible to use both as independent variables in the regression equations. AGP binds also the positively 
charged compounds, however, there is a different steric hindrance for molecules that have bulky 
substitutions near the positive charge [62]. Although AGP can be found in human plasma at low 
concentrations (approximately 1.5 %) it may be significant in clinical investigations as its concentration 
depends on the disease state and can increase significantly [63]. Therefore compounds’ strong binding to 
AGP should be avoided as it may cause variable free concentrations of the drug in patients with various 
diseases. The model to estimate total plasma protein binding (log k(PPB)) includes the AGP binding as is 
shown by Equation 8 [64]. 
log 𝑘 (𝑃𝑃𝐵) = 0.87 ∗ log 𝑘(𝐻𝑆𝐴) + 0.17 ∗ log 𝑘(𝐴𝐺𝑃) + 0.06 ∗ 𝑐𝑀𝑅 − 0.27     (8) 
n = 55      r2 = 0.85     s=0.36 
cMR is the calculated molar refraction of the compounds related to the size of the molecules and 
accounts for the non-specific binding of the compounds to immunoglobulins in the plasma. 
 AGP also represents important cellular components such as glycoprotein in general. There has been 
observed overlapping binding between AGP and P-glycoprotein [65]. Also, the mucus in human airways is 
composed predominantly of glycoproteins. Several tissue binding models include the AGP binding, such as 
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mucus binding showed good correlation to AGP binding (r2 = 0.85) [66] and lung tissue binding showed 
good correlations with the weighted sum of HSA and AGP bindings [67].  
Conclusions 
Established screening procedures in pharmaceutical drug discovery companies cause significant delays 
in getting a compound to market.  One reason is that the initial discovery phase typically prioritises 
optimising discovery molecules to bind with high affinity to the target receptor. Drug analogues typically 
possess high receptor occupancy, which is anticipated to have better efficacy and selectivity, i.e., reduced 
off-target pharmacology. The insight lacking during this process is that all the potent analogues may not 
have the ADME properties to elicit sufficient free concentration of the drug near the receptor. We have 
presented an HPLC based technology by which the drug discovery process can be accelerated by 
chromatographic profiling of the analogues to model the in vivo drug disposition. The proposed 
methodology is able to identify compounds that have a greater probability of having acceptable in vivo 
properties. The methodology has been compared to Ligand Lipophilicity Efficiency (LLE) parameter that is 
used early in the lead optimization process. There is an inverse correlation between the maximum drug 
efficiency and clogP, thus LLE incorporates similar efficiency metrics as DEI. While clogP can be easily 
calculated and the drug efficiency requires simple HPLC based measurements, the advantage is that it 
mimics the biological non-specific binding more accurately than calculated octanol/water lipophilicity. The 
measured IAM MB/PB incorporates the effect of charge and shape of the molecules on the binding to real 
body components which are not reflected in their distribution in octanol and water. The technology is 
suitable for estimating the tissue binding, plasma protein binding, volume of distribution, unbound volume 
of distribution, drug efficiency, promiscuity, phospholipidotic potential, etc. Therefore, this technology is 
recommended for use in early drug discovery programmes to aid the compound triage process so that only 
compounds with a higher probability of having good affinity along with good ADME properties are selected 
for progression to expensive animal studies. The technology is commercially available; the models have 
been published in a book titled “Physicochemical and Biomimetic Properties in Drug Discovery: 
Chromatographic Techniques for Lead Optimisation” [45] and are encouraged to be routinely used in the 
early drug discovery process.   
The conclusion is that in vivo data should not be generated until the compounds have been analysed by 
chromatographic techniques, and only compounds that are predicted to have optimal in vivo properties 
should be progressed for further analysis. The proposed alternate drug discovery process should include (i) 
potency evaluation or receptor binding and (ii) predictive in vivo properties of each analogues. Only after 
both of these steps are completed should compounds be chosen for further development by extensive 
testing both in vitro and in vivo.  Using this approach will eliminate numerous candidates from the pool of 
active analogues and has the potential to help save considerable amounts of time and money during the 
process of getting NCE’s  to market.  Even if only 5-10 compounds are immediately eliminated as drug 
candidates, this potentially saves millions of dollars in the cost to get a drug to market.   
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t1/2 (h) Log 
t1/2 
(h) 
ABACAVIR Test 600 7.2 2 0.84 -0.08 1.68 0.23 13.00 1.11 1.00 0.00 
ACEBUTOLOL 
HYDROCHLORIDE 
Test 400 6.8 2 1.7 0.23 2.30 0.36 10.00 1.00 3.50 0.54 
ACETYLSALICYLIC 
ACID 
Train. 1200 5.5 3 0.22 -0.66 0.32 -0.49 12.00 1.08   
ACRIVASTINE Test 32 8.5 4       1.50 0.18 
ALBUTEROL 
SULFATE 
Test 8 7.4 4 1.9 0.28 2.07 0.31 7.80 0.89 2.40 0.38 
ALLOPURINOL Test 300 5.3 1 0.58 -0.24 0.60 -0.22 11.00 1.04 0.80 -0.10 
ALOSETRON 
HYDROCHLORIDE 
Train. 1 7.3 2 1.1 0.04 6.11 0.79 8.70 0.94 1.60 0.20 
AMILORIDE 
HYDROCHLORIDE 
Test 5 5.5 1 5 0.70     7.50 0.88 
AMINO-
GLUTETHIMIDE 
Test 500 4.9 2       12.50 1.10 
AMITRIPTYLINE 
HYDROCHLORIDE 
Test 50 6.2 1 8.7 0.94 124.29 2.09 6.10 0.79 17.00 1.23 
AMOXAPINE Train. 300 6.5 3         
ARIPIPRAZOLE Test 10 9.7 1 4.9 0.69 490.00 2.69 0.83 -0.08 75.00 1.88 
ATOMOXETINE 
HYDROCHLORIDE1 
Test 40 8.7 1 0.85 -0.07 42.50 1.63 9.30 0.97 5.20 0.72 
BENDRO-
FLUMETHIAZIDE 
Test 3 3.4 1       8.50 0.93 
BICALUTAMIDE Test 50 6.1 1       144.00 2.16 
BUPROPION 
HYDROCHLORIDE 
Test 300 6.3 1       24.00 1.38 
CABERGOLINE Test 0 10 0     45.71 1.66 65.00 1.81 
CAFFEINE Test 150 4.7 3 0.63 -0.20 0.98 -0.01 1.40 0.15 4.90 0.69 
CANDESARTAN 
CILEXETIL 
Test 8 10.5 1 0.13 -0.89 13.00 1.11 0.37 -0.43 9.00 0.95 
CARBAMAZEPINE Train. 800 4.6 1       17.00 1.23 
CELECOXIB Test 400 8.5 2 6.13 0.79 204.33 2.31 6.59 0.82 11.00 1.04 
CILOSTAZOL Test 200 6.7 2       12.00 1.08 
CITALOPRAM 
HYDROBROMIDE 
Test 20 8.3 1 12 1.08 60.00 1.78 4.30 0.63 33.00 1.52 
CLOMIPRAMINE 
HYDROCHLORIDE 
Test 25 7.9 1 13 1.11 433.33 2.64 8.20 0.91 26.00 1.41 
CLONIDINE 
HYDROCHLORIDE 
Train. 0 8.5 1 3.3 0.52 5.89 0.77 4.00 0.60 7.60 0.88 
DAPSONE Test 100 4.8 1 0.83 -0.08 3.32 0.52 0.48 -0.32 22.00 1.34 
DESLORATADINE Test 5 9.4 1       50.00 1.70 
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DIAZOXIDE Train. 150 4.7 3 0.21 -0.68 3.50 0.54 0.06 -1.22 48.00 1.68 
DIDANOSINE Test 250 8 2 0.77 -0.11 0.81 -0.09 11.00 1.04 1.40 0.15 
DIFLUNISAL Train. 1000 4.2 2 0.1 -1.00   0.10 -1.00 10.00 1.00 
DIPHENHYDRAMINE 
HYDROCHLORIDE 
Train. 75 8.1 3 6.5 0.81 34.21 1.53 9.80 0.99 9.30 0.97 
DIPYRIDAMOLE Train. 200 6.7 2 1.75 0.24 175.00 2.24 3.00 0.48 0.70 -0.15 
DOMPERIDONE Test 30 9.8 3 3.4 0.53 42.50 1.63 9.50 0.98 7.50 0.88 
DONEPEZIL 
HYDROCHLORIDE 
Test 5 8.2 1 12 1.08 300.00 2.48 2.17 0.34 70.00 1.85 
EFAVIRENZ Test 600 8.9 1       47.00 1.67 
ETODOLAC Test 600 6.2 2 0.39 -0.41 39.00 1.59 0.82 -0.09 7.30 0.86 
FELBAMATE Train. 1200 3.4 3 0.76 -0.12 1.09 0.04 0.50 -0.30 22.00 1.34 
FELODIPINE Train. 5 9.8 1 4.4 0.64   11.00 1.04 10.00 1.00 
FEXOFENADINE 
HYDROCHLORIDE 
Test 60 7.3 2       14.40 1.16 
FINASTERIDE Train. 5 7.3 1 0.89 -0.05 5.56 0.75 4.70 0.67 3.00 0.48 
FLUOXETINE 
HYDROCHLORIDE 
Train. 60 8.6 1 32.5 1.51 541.67 2.73   48.00 1.68 
FLURBIPROFEN Train. 200 6.2 4 0.12 -0.92     5.00 0.70 
FLUTAMIDE Test 750 5.9 3       6.00 0.78 
FLUVOXAMINE 
MALEATE 
Test 50 8.3 1 25 1.40 125.00 2.10   15.60 1.19 
FUROSEMIDE Train. 80 5 2 0.12 -0.92 12.00 1.08 1.60 0.20 2.50 0.40 
GLIBENCLAMIDE Test 3 5.3 1 0.13 -0.89 13.00 1.11 1.30 0.11 1.60 0.20 
GLIMEPIRIDE Test 1 5.4 1 0.19 -0.72 19.00 1.28 0.50 -0.30 10.00 1.00 
GLIPIZIDE Train. 3 5.5 1 0.16 -0.80 8.00 0.90 0.56 -0.25 3.30 0.52 
GRANISETRON 
HYDROCHLORIDE 
Test 2 9.9 2 3.7 0.57 10.57 1.02 9.10 0.96 5.20 0.72 
GUANABENZ 
ACETATE 
Test 8 8.2 2       6.00 0.78 
HALOPERIDOL Test 2 10 2 17 1.23 212.50 2.33 7.80 0.89 35.00 1.54 
HYDROCHLOROTHIA
ZIDE 
Test 50 4.7 2       8.00 0.90 
IMIPRAMINE 
HYDROCHLORIDE 
Train. 75 6.6 1 12 1.08 150.00 2.18 13.00 1.11 16.00 1.20 
INDAPAMIDE Test 1 4.2 1       14.00 1.15 
INDOMETHACIN Train. 75 6.5 3 0.1 -1.00 10.00 1.00 1.30 0.11 1.40 0.15 
IRBESARTAN Test 150 9.3 1 0.94 -0.03 9.40 0.97 2.30 0.36 14.00 1.15 
ISRADIPINE Test 5 6.6 2 1.5 0.18 37.50 1.57 26.00 1.41 3.30 0.52 
KETOCONAZOLE Train. 200 4.7 1       2.00 0.30 
KETOPROFEN Train. 225 7.6 3 0.13 -0.89 1.63 0.21 1.60 0.20 2.10 0.32 
LAMOTRIGINE Test 25 4 1 1.1 0.04 2.44 0.39 0.58 -0.24 25.00 1.40 
LANSOPRAZOLE Test 15 7.1 1 0.28 -0.55 14.00 1.15 4.40 0.64 1.00 0.00 
LEFLUNOMIDE Test 100 4.9 1 0.13 -0.89 13.00 1.11   336.00 2.53 
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LETROZOLE Test 3 7.9 1 1.9 0.28 4.63 0.67 0.57 -0.24 45.00 1.65 
LORAZEPAM Train. 3 8.9 3 1.3 0.11 14.44 1.16 1.00 0.00 17.00 1.23 
LOVASTATIN Test 10 9.5 1 0.87 -0.06 21.75 1.34 7.20 0.86 1.40 0.15 
LOXAPINE 
SUCCINATE 
Test 40 8.3 2       4.00 0.60 
MAPROTILINE 
HYDROCHLORIDE 
Train. 75 4.4 3 45 1.65 409.09 2.61 14.00 1.15 51.00 1.71 
MEBENDAZOLE Train. 200 6.7 2 1.2 0.08 13.33 1.12 15.00 1.18 1.10 0.04 
MERCAPTOPURINE Test 3 4.8 1 1 0.00 1.18 0.07 15.00 1.18 1.00 0.00 
METHYL-
PREDNISOLONE 
Train. 4 6.3 1 1.2 0.08 5.22 0.72 6.10 0.79 2.30 0.36 
METOCLOPRAMIDE 
HYDROCHLORIDE 
Test 20 8.4 2 3.2 0.51 5.33 0.73 5.70 0.76 7.20 0.86 
METOLAZONE Test 3 5.7 1       14.00 1.15 
MIANSERIN Train. 60 8.1 2       13.50 1.13 
MIBEFRADIL 
DIHYDROCHLORIDE 
Test 50 6.2 1 3.1 0.49 310.00 2.49 4.00 0.60 13.00 1.11 
MIFEPRISTONE Test 600 8 1       18.00 1.26 
MYCOPHENOLIC 
ACID 
Test 1440 8 2 0.77 -0.11 38.50 1.59 2.00 0.30 12.00 1.08 
NADOLOL Train. 40 8.9 1 1.9 0.28 13.57 1.13 2.90 0.46 9.20 0.96 
NAPROXEN Train. 1000 5.2 2       15.00 1.18 
NEOSTIGMINE 
BROMIDE 
Train. 15 7.4 1 0.74 -0.13   9.20 0.96 1.30 0.11 
NEVIRAPINE Test 200 8 1 1.3 0.11 4.06 0.61 0.30 -0.52 53.00 1.72 
NICARDIPINE 
HYDROCHLORIDE 
Train. 60 5.6 2 1 0.00 100.00 2.00 11.00 1.04 4.10 0.61 
NIMESULIDE Test 400 4.4 2       2.80 0.45 
NIMODIPINE Test 120 9.6 4 1.1 0.04 55.00 1.74 15.00 1.18 1.30 0.11 
NISOLDIPINE Test 20 9.8 1 5.5 0.74   15.00 1.18 11.00 1.04 
NITRENDIPINE test 20 7.6 2 6.1 0.79 305.0 2.48 25.00 1.40 8.20 0.91 
NORTRIPTYLINE 
HYDROCHLORIDE 
Train. 75 9 3 22 1.34 183.33 2.26 10.00 1.00 30.00 1.48 
OLANZAPINE Test 10 7.5 1 14.3 1.16 204.29 2.31 7.14 0.85 37.50 1.57 
PENTOXIFYLLINE Train. 800 3.7 2 1.8 0.26 6.00 0.78 39.00 1.59 1.20 0.08 
PERGOLIDE 
MESYLATE 
Test 0 8.9 1       27.00 1.43 
PHENYTOIN Train. 90 4.2 1       22.00 1.34 
PIMOZIDE Test 8 9.6 2       29.30 1.47 
PIOGLITAZONE 
HYDROCHLORIDE 
Test 15 4.5 1 0.63 -0.20 63.00 1.80   5.00 0.70 
PIROXICAM Train. 20 6.7 1 0.14 -0.85 2.33 0.37   58.00 1.76 
PRAVASTATIN 
SODIUM 
Test 40 8.2 1 0.46 -0.34 0.92 -0.04 14.00 1.15 0.80 -0.10 
PRAZOSIN 
HYDROCHLORIDE 
Train. 2 8.9 3 0.73 -0.14 12.17 1.09 4.70 0.67 2.00 0.30 
PRIMAQUINE 
PHOSPHATE 
Test 15 5.4 1 4 0.60   5.80 0.76 7.10 0.85 
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PROBENECID Train. 1000 3.8 2 0.13 -0.89 1.00 0.00 0.25 -0.60 5.90 0.77 
PROCHLORPERAZIN
E MALEATE 
Test 15 8.5 3 22 1.34   16.00 1.20 9.00 0.95 
PROCYCLIDINE 
HYDROCHLORIDE 
Test 8 8.6 3 0.74 -0.13   0.86 -0.07 12.00 1.08 
PROMETHAZINE 
HYDROCHLORIDE 
Test 50 8.2 2 14 1.15 155.56 2.19 14.00 1.15 14.00 1.15 
PROPAFENONE 
HYDROCHLORIDE 
Test 450 5.7 3 2.2 0.34 55.00 1.74 16.00 1.20 2.10 0.32 
PROPRANOLOL HCL Train. 160 9.4 2 3.1 0.49 23.85 1.38 12.00 1.08 3.40 0.53 
PROTRIPTYLINE 
HYDROCHLORIDE 
Test 15 5.6 3 22 1.34       
QUININE SULFATE Train. 1800 6.3 6 1.8 0.26 6.00 0.78 1.90 0.28 11.00 1.04 
RILUZOLE Test 100 4.4 2       12.00 1.08 
ROXITHROMYCIN Test 450 6.8 3   0.00    12.00 1.08 
SAQUINAVIR Test 2000 8.3 2 3.6 0.56 120.00 2.08 13.00 1.11 13.00 1.11 
SIMVASTATIN Test 40 8.4 1       3.00 0.48 
SULFINPYRAZONE Train. 100 3.3 1 0.12 -0.92 6.00 0.78 0.34 -0.47 6.20 0.79 
SUMATRIPTAN Test 75 8.1 3 1.7 0.23 2.05 0.31 19.00 1.28 1.70 0.23 
TAMSULOSIN 
HYDROCHLORIDE 
Test 2 11 2 0.21 -0.68 21.00 1.32 0.62 -0.21 6.80 0.83 
TRAZODONE 
HYDROCHLORIDE 
Train. 150 6.3 1 0.52 -0.28   1.40 0.15 7.30 0.86 
VENLAFAXINE 
HYDROCHLORIDE 
Test 75 7.7 2 4.4 0.64 6.03 0.78 14.00 1.15 5.00 0.70 
VERAPAMIL 
HYDROCHLORIDE 




Table A2. Measured biomimetic properties and estimated volume of distribution, unbound volume of distribution 





), log K(HSA)= exp(logk(HSA); log K(IAM) obtained from measured IAM MB as described by 
Equation (1); IAM MB/PB DEmax is calculated from Vdu as 100/Vdu where log Vdu is obtained as a sum of log K(IAM) 
and log K(HSA) according to Equation (4); IAM MB/PB log Vdss is obtained from the difference between log K(IAM) 
and log K(HSA) as described by Equation 3. The test/training marks are based whether it was used in the model 





























ABACAVIR test 31.9 0.71 1.77 60.9 0.21 -0.04 Weak Base 
ACEBUTOLOL 
HYDROCHLORIDE 
test 32.7 0.73 1.59 72.1 0.13 -0.12 Basic 
ACETYLSALICYLIC ACID test 66.4 1.33         Acidic 
ACRIVASTINE test 82.5 1.91 2.68 13.2 0.87 0.10 Weak Base 
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ALBUTEROL SULFATE test 22 0.57 1.55 81.6 0.08 -0.10 Basic 
ALLOPURINOL  19.2 0.53 2 54.9 0.26 0.10 Acidic 
ALOSETRON 
HYDROCHLORIDE 
test 75.5 1.60 2.68 15.8 0.80 0.17 Weak Base 
AMILORIDE 
HYDROCHLORIDE 
training 38.6 0.81 2.56 27.3 0.57 0.29 Acidic 
AMINOGLUTETHIMIDE training 25.9 0.63 1.53 81 0.08 -0.13 Weak Base 
AMITRIPTYLINE 
HYDROCHLORIDE 
test 90.1 2.50 6.3 0.308 2.56 1.56 Basic 
AMOXAPINE test 88.4 2.33 6.64 0.24 2.67 1.75 Basic 
ARIPIPRAZOLE test 97.8 4.42 6.08 0.129 2.91 1.04 Basic 
ATOMOXETINE 
HYDROCHLORIDE1 
test 87.5 2.25 5.28 0.922 2.07 1.17 Basic 
BENDROFLUMETHIAZIDE test 64.4 1.28 2.95 12.7 0.84 0.36 Weak Acid 
BICALUTAMIDE test 96.8 3.91 3.21 2.66 1.56 -0.11 Neutral 
BUPROPION 
HYDROCHLORIDE 
test  73.9 1.55 3.21 9.7 1.02 0.41 Basic 
CABERGOLINE test 83.6 1.98 6.41 0.366 2.49 1.73 Basic 
CAFFEINE test 26.8 0.64 1.22 108 -0.05 -0.26 Neutral 
CANDESARTAN CILEXETIL test 97.9 4.48 3.8 1.07 1.94 0.03 Acidic 
CARBAMAZEPINE test 79.9 1.78 2.34 19.7 0.70 -0.02 Neutral 
CELECOXIB test 97.1 4.04 3.9 1.24 1.89 0.17 Neutral 
CILOSTAZOL test 89.9 2.48 3.02 6.97 1.15 0.12   
CITALOPRAM 
HYDROBROMIDE 
test 72.4 1.50 4.85 2.12 1.71 1.14 Basic 
CLOMIPRAMINE 
HYDROCHLORIDE 
test 94.4 3.18 7.6 0.06 3.28 1.99 Basic 
CLONIDINE 
HYDROCHLORIDE 
test 37.7 0.80 1.96 48.9 0.31 0.03 Basic 
DAPSONE test 80.6 1.82 2.07 25 0.59 -0.15 Neutral 
DESLORATADINE test 88.5 2.34 6.13 0.39 2.45 1.52 Basic 
DIAZOXIDE training 77.6 1.68 2.05 27.3 0.55 -0.13 Acidic 
DIDANOSINE test 27.5 0.65        Weak Acid 
DIFLUNISAL test 98.8 5.22 2.49 2.57 1.55 -0.71 Acidic 
DIPHENHYDRAMINE 
HYDROCHLORIDE 
test 68.7 1.39 2.98 13.3 0.88 0.35 Basic 
DIPYRIDAMOLE test 88.2 2.31 4.03 2.93 1.54 0.60 Weak Base 
DOMPERIDONE test 92.2 2.77 3.96 2.43 1.62 0.47 Basic 
DONEPEZIL 
HYDROCHLORIDE 
test 86.1 2.14 3.68 4.45 1.36 0.49 Basic 
EFAVIRENZ test 97.3 4.14 4.34 0.777 2.10 0.34   
ETODOLAC test 95.6 3.48 2.51 6.52 1.16 -0.32 Acidic 
FELBAMATE test 68.7 1.39 1.76 42.3 0.36 -0.19 Neutral 
FELODIPINE test 95.9 3.58 4.45 0.965 2.02 0.51 Neutral 




test 74.1 1.55 2.64 16.6 0.77 0.16 Basic 
FINASTERIDE test 88.4 2.33 3.34 5.55 1.25 0.30   
FLUOXETINE 
HYDROCHLORIDE 
test 91.2 2.63 6.19 0.305 2.55 1.48 Basic 
FLURBIPROFEN test 98.6 5.02 1.99 4.77 1.29 -0.89 Acidic 
FLUTAMIDE test 94.3 3.15 3.48 3.11 1.50 0.18 Neutral 
FLUVOXAMINE MALEATE test 72.3 1.49 5.15 1.59 1.84 1.28 Basic 
FUROSEMIDE test 89.7 2.46 2.14 12.4 0.77 -0.26 Acidic 
GLIBENCLAMIDE test 98 4.55 2.7 2.99 1.49 -0.47 Acidic 
GLIMEPIRIDE test 98 4.55 2.53 3.61 1.41 -0.55 Acidic 
GLIPIZIDE test 95.8 3.54 1.83 12 0.88 -0.63 Acidic 
GRANISETRON 
HYDROCHLORIDE 
test 69 1.40 4.34 3.57 1.47 0.94 Basic 
GUANABENZ ACETATE test 88.1 2.30 4.85 1.36 1.90 0.97 Basic 
HALOPERIDOL test 90.4 2.54 4.6 1.46 1.84 0.81 Basic 
HYDROCHLOROTHIAZIDE test 45.4 0.92 1.62 63.3 0.19 -0.15   
IMIPRAMINE 
HYDROCHLORIDE 
test 86.3 2.16 4.23 2.63 1.59 0.73 Basic 
INDAPAMIDE test 75.1 1.59 2.6 17.1 0.76 0.13 Weak Acid 
INDOMETACIN test 98.6 5.02 2.34 3.33 1.44 -0.74 Acidic 
IRBESARTAN test 96.1 3.64 2.17 8.18 1.05 -0.51 Acidic 
ISRADIPINE test 94.4 3.18 3.48 3.05 1.51 0.17 Neutral 
KETOCONAZOLE training 94.6 3.22 3.59 2.69 1.56 0.21 Weak Base 
KETOPROFEN test 98.4 4.85 2.18 4.3 1.33 -0.77 Acidic 
LAMOTRIGINE test 59.5 1.17 1.99 38.5 0.40 -0.04 Weak Base 
LANSOPRAZOLE test 90.5 2.55 2.66 9.45 1.01 -0.05   
LEFLUNOMIDE test 92.6 2.84 3.37 4.07 1.38 0.20 Neutral 
LETROZOLE test 59.3 1.17 2.42 25.7 0.59 0.15 Neutral 
LORAZEPAM test 91.1 2.62 3.16 5.67 1.24 0.15 Neutral 
LOVASTATIN test 95.5 3.45 4.09 1.47 1.83 0.38 Neutral 
LOXAPINE SUCCINATE test 92.7 2.85 5.28 0.658 2.21 1.04 Basic 
MAPROTILINE 
HYDROCHLORIDE 
training 86 2.13 6.7 0.25 2.65 1.82 Basic 
MEBENDAZOLE test 92.9 2.89 3.07 5.25 1.26 0.06 Weak Base 
MERCAPTOPURINE test 41.2 0.85         
METHYLPREDNISOLONE test 71.9 1.48 2.6 18.2 0.74 0.16 Neutral 
METOCLOPRAMIDE 
HYDROCHLORIDE 
test 58.9 1.16 3.54 8.87 1.07 0.64 Basic 
METOLAZONE test 83.8 1.99 2.49 15.2 0.81 0.00 Neutral 
MIANSERIN test 91.9 2.73 5.47 0.595 2.26 1.15 Basic 
MIBEFRADIL 
DIHYDROCHLORIDE 
test 93.6 3.01 6.3 0.231 2.68 1.45 Basic 
MIFEPRISTONE test 95.5 3.45 4.2 1.33 1.88 0.43   
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MYCOPHENOLIC ACID test 95.5 3.45 1.83 12.7 0.86 -0.61 Acidic 
NADOLOL test 39.7 0.83 1.76 58.5 0.23 -0.07   
NAPROXEN test 99.9 7.09 1.96 1.55 1.75 -1.36 Acidic 
NEOSTIGMINE BROMIDE test 87.6 2.26 1.68 28.1 0.52 -0.42 Basic 
NEVIRAPINE test 54 1.06 1.89 45 0.34 -0.06 Neutral 
NICARDIPINE 
HYDROCHLORIDE 
test 95.8 3.54 4.23 1.21 1.91 0.42 Weak Base 
NIMESULIDE test 98 4.55 2.32 4.4 1.32 -0.64 Acidic 
NIMODIPINE test 92 2.74 3.09 5.64 1.24 0.10 Neutral 
NISOLDIPINE test 91 2.61 3.16 5.67 1.24 0.16 Neutral 
NITRENDIPINE test 93.9 3.07 3.59 2.88 1.53 0.24 Neutral 
NORTRIPTYLINE 
HYDROCHLORIDE 
training 86.2 2.15 5.66 0.673 2.21 1.36 Basic 
OLANZAPINE test 86.2 2.15 5.06 1.2 1.95 1.09 Basic 
PENTOXIFYLLINE test 25.9 0.63 1.47 85.5 0.06 -0.15 Neutral 
PERGOLIDE MESYLATE test 85.2 2.08 5.71 0.672 2.21 1.40 Basic 
PHENYTOIN test 83.4 1.97 2.51 15.1 0.81 0.01 Weak Acid 
PIMOZIDE test 98.6 5.02 5.61 0.142 2.85 0.70 Basic 
PIOGLITAZONE 
HYDROCHLORIDE 
test 97.9 4.48 2.76 2.97 1.50 -0.43   
PIROXICAM test 97.3 4.14 1.9 8.14 1.05 -0.73 Acidic 
PRAVASTATIN SODIUM test 40.3 0.84 1.83 54 0.26 -0.04 Acidic 
PRAZOSIN 
HYDROCHLORIDE 
test 85.2 2.08 2.47 14.6 0.82 -0.03 Weak Base 
PRIMAQUINE PHOSPHATE test 79.2 1.75 4.6 2.31 1.66 0.98 Basic 
PROBENECID training 95.4 3.43 1.81 13.2 0.85 -0.62 Acidic 
PROCHLORPERAZINE 
MALEATE 
test 96.9 3.95 7.67 0.037 3.49 1.85 Basic 
PROCYCLIDINE 
HYDROCHLORIDE 
test 86.1 2.14 4.49 1.72 1.70 0.84 Neutral 
PROMETHAZINE 
HYDROCHLORIDE 
test 92.5 2.82 7.2 0.107 3.02 1.89 Basic 
PROPAFENONE 
HYDROCHLORIDE 
training 88 2.29 4.38 2.1 1.69 0.76 Basic 
PROPRANOLOL HCL test 72.7 1.51 4.45 3.04 1.54 0.97 Basic 
PROTRIPTYLINE 
HYDROCHLORIDE 
test 83.8 1.99 5.42 0.929 2.07 1.29 Basic 
QUININE SULFATE test 78.1 1.70 5.19 1.35 1.90 1.25 Basic 
RILUZOLE test 94.2 3.13 3.29 3.71 1.41 0.10 Weak Base 
ROXITHROMYCIN test 46.6 0.93 5.37 1.88 1.80 1.50   
SAQUINAVIR test 95.2 3.37 3.77 2.07 1.68 0.26 Weak Base 
SIMVASTATIN test 96.6 3.82 4.49 0.823 2.09 0.47   
SULFINPYRAZONE training 97.2 4.09 2.11 6.83 1.13 -0.63 Acidic 
SUMATRIPTAN test 28 0.66 2.68 26.5 0.58 0.37 Basic 




test 68.9 1.39 2.84 14.8 0.82 0.28 Basic 
TRAZODONE 
HYDROCHLORIDE 
test 92 2.74 3.04 5.81 1.22 0.07 Weak Base 
VENLAFAXINE 
HYDROCHLORIDE 
test 35 0.76 3.19 15.5 0.83 0.58 Basic 
VERAPAMIL 
HYDROCHLORIDE 
test 88.1 2.30 3.59 3.93 1.35 0.41 Basic 
ZAFIRLUKAST test 99.1 5.57 3.67 0.789 2.14 -0.27 Acidic 
ZALCITABINE test 23.6 0.60         Zwitterionic 
ZIDOVUDINE test 11.9 0.42 1.17 127 -0.12 -0.24 Weak Acid 
ZILEUTON training 89.7 2.46 2.53 10.46 0.93 -0.09 Neutral 
ZIPRASIDONE 
HYDROCHLORIDE 
training 97.2 4.09 4.64 0.596 2.22 0.48 Weak Base 
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